FOLH1 and prostate carcinoma: Indeed, in a BRCA2-mutated prostate cancer xenograft model, PSMA-TTC plus the PARP inhibitor olaparib showed more notable anti-tumor activity than PSMA-TTC alone, while olaparib alone showed no activity (67).